Cigna's most recent trend suggests a bearish bias. One trading opportunity on Cigna is a Bear Call Spread using a strike $195.00 short call and a strike $210.00 long call offers a potential 6.23% return on risk over the next 35 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $195.00 by expiration. The full premium credit of $0.88 would be kept by the premium seller. The risk of $14.12 would be incurred if the stock rose above the $210.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Cigna is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Cigna is bearish.
The RSI indicator is at 63.46 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Cigna
Edited Transcript of CI earnings conference call or presentation 2-Aug-18 12:30pm GMT
Wed, 15 Aug 2018 13:40:23 +0000
Q2 2018 Cigna Corp Earnings Call
Carl Icahn starts positions in Cigna, Dell, VMware
Tue, 14 Aug 2018 21:34:00 +0000
MARKET PULSE Activist investor Carl Icahn started a few new positions over the last quarter and added to his stakes in Icahn Enterprises LP (iep) and Herbalife Nutrition Ltd. (hlf) according to a filing with the Securities and Exchange Commission late Tuesday.
Icahn's Retreat May Hand Cigna a Pyrrhic Victory
Tue, 14 Aug 2018 16:04:55 +0000
Cigna Corp. won an unusual and very fast victory against Carl Icahn. The activist investor announced Monday night that he was dropping his nascent effort to block the health insurer’s $54 billion takeover of pharmacy benefit management giant Express Scripts Holding Co. Cigna may end up regretting its win, though.
Icahn won't solicit votes against Cigna-Express Scripts deal
Tue, 14 Aug 2018 12:56:26 +0000
The octogenarian investor originally opposed the deal due to the competitive risk Express Scripts and Cigna now face from Amazon.
Icahn ends Cigna-Express Scripts campaign, shares bounce
Tue, 14 Aug 2018 12:23:07 +0000
Shares of Express Scripts are moving higher before the opening bell after activist investor Carl Icahn ended a short-lived fight to scuttle Cigna's takeover of the pharmacy benefit manager. Icahn said late Monday that he'll end his campaign to convince Cigna shareholders to vote against the roughly $52-billion deal this month. Icahn argued in a lengthy letter to fellow shareholders last week that Cigna was “dramatically overpaying” for Express Scripts.
Related Posts
Also on Market Tamer…
Follow Us on Facebook